Welcome to our dedicated page for FSTX news (Ticker: FSTX), a resource for investors and traders seeking the latest updates and insights on FSTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSTX's position in the market.
F-star Therapeutics, Inc. (NASDAQ: FSTX) announced its first quarter 2022 financial results, highlighting significant clinical advancements and corporate developments. The company reported cash and cash equivalents of $68.8 million, down from $78.5 million at year-end. R&D expenses increased to $8.0 million, while G&A expenses decreased to $5.7 million. The net loss attributable to shareholders was $12.1 million, representing a loss per share of $0.57. F-star anticipates four clinical readouts in 2022 and has expanded its clinical programs in Europe, further enhancing shareholder value.
F-star Therapeutics, a clinical-stage biopharmaceutical firm, is set to hold a conference call on May 10, 2022, at 9:00 a.m. EST to discuss its first quarter 2022 financial results and corporate updates. Investors can join via a live webcast or by phone. The company focuses on next-generation immunotherapies, utilizing tetravalent bispecific antibodies to advance cancer treatment. With over 500 patents related to its innovative antibody discovery platform, F-star is engaged in partnerships targeting critical unmet medical needs in oncology and beyond.
F-star Therapeutics (NASDAQ: FSTX) announced new preclinical data on its bispecific antibody FS118, targeting LAG-3 and PD-L1, to be presented at the AACR Annual Meeting in April 2022. FS118 demonstrated a unique tetravalent structure, crucial for enhancing LAG-3 shedding and reducing its surface expression in tumor-infiltrating lymphocytes (TILs). This mechanism may help overcome the limitations of existing immunotherapies. The data is anticipated to provide insights into FS118's potential in combating immunotherapy resistance.
F-star Therapeutics (FSTX) announced its 2021 financial results and highlighted multiple upcoming clinical program updates. The company secured two partnerships with Janssen and AstraZeneca and significantly increased its cash position to $78.5M. Key clinical trials like FS222 and FS120 are progressing, with results expected in 2022. R&D expenses rose sharply to $28.8M, while the net loss grew to $31.3M or ($1.88) per share. The company aims for transformative readouts in its various bispecific antibody therapies.
F-star Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 32nd Annual Oppenheimer Healthcare Conference, scheduled for March 15-17, 2022. The company's CEO, Eliot Forster, will present on March 17, 2022, from 12:40 PM to 1:10 PM ET. F-star is focusing on advancing next-generation immunotherapies, particularly utilizing bispecific antibodies for cancer treatment. The company boasts over 500 patents and is actively engaged in partnerships addressing unmet needs across oncology and other areas.
F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced a conference call scheduled for March 14, 2022, at 9:00 a.m. EST to discuss its fourth quarter and full-year 2021 financial results and provide a corporate update. Investors can access the call via a live webcast or by phone. F-star is focused on developing innovative immunotherapies for cancer treatment and has several second-generation therapeutics in the clinic, employing its proprietary antibody discovery platform backed by over 500 patents.
F-star Therapeutics (NASDAQ: FSTX) appointed James Sandy as Chief Development Officer on March 1, 2022. Sandy, with over 35 years in drug development, will enhance F-star's oncology pipeline. CEO Eliot Forster emphasized Sandy's expertise in accelerating clinical operations. Sandy's previous roles include Chief Development Officer at Ellipses Pharma and Immunocore. In connection with his appointment, Sandy received a stock option grant of 50,000 shares and 25,000 restricted stock units, both vesting over four years, contingent on continued service.
F-star Therapeutics announced the issuance of U.S. Patent No. 11,214,620, granting protection for its bispecific antibody FS118, which blocks PD-L1 and LAG-3 receptors. This patent extends exclusivity until at least August 2038, strengthening F-star's intellectual property portfolio, which comprises over 500 granted and pending patents. Chief Scientific Officer Neil Brewis highlighted the patent's significance in supporting the commercial potential of FS118 and the company's strategy for growth in immunotherapy.
F-star Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two important conferences: the H.C. Wainwright Bioconnect Conference and the B. Riley Securities’ Oncology Conference, taking place virtually from January 10-13 and January 27-28, 2022, respectively. CEO Eliot Forster will present the company’s corporate strategy and bispecific antibody discovery platform, showcasing four clinical-stage programs. Recorded sessions will be accessible on F-star's website for 90 days post-conference.
F-star Therapeutics, Inc. (NASDAQ: FSTX) announced that Ares Trading S.A., a Merck KGaA affiliate, has exercised a fourth licensing option for a bispecific program under their collaboration. Merck KGaA will cover all future development costs and pay success-based milestones, with potential revenue for F-star estimated at $765 million. CEO Eliot Forster expressed excitement over recent data from Merck's presentations, highlighting the collaboration's significance in advancing immuno-oncology therapies.
